Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Next Previous
Trial Profile

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; MRNA-4359 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Sodium chloride
  • Indications Advanced breast cancer; Basal cell cancer; Bladder cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Moderna Therapeutics

Most Recent Events

  • 01 May 2026 According to Moderna Therapeutics media release, . The Company recently presented mRNA-4359 data at the American Association for Cancer Research (AACR) 2026 Annual Meeting.
  • 17 Apr 2026 Results presented in the Moderna Therapeutics media release.
  • 17 Apr 2026 According to Moderna Therapeutics media release, data from this trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 17-22, 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top